Launch Of Vyvgart Exceeds Argenx’s Expectations
‘Pipeline in A Product’ Off To Strong Start In US
Tim Van Hauwermeiren, CEO of Argenx, has been on the road with the firm's field force for the US launch of Vyvgart for generalized myasthenia gravis and has been enthused by the positive response from physicians.
